This book provides readers with the most up-to-date practical information on breast cancer screening. Since breast cancers are highly heterogeneous, time to clinical onset from the initial carcinogenesis differs diversely between cancers. Pathological germline variants and driver mutations cause a high lifetime risk of breast cancer. The lifetime risks are various according to what genes are pathologically dysfunctional. Integrated omics and imaging technologies have established varying tumour characteristics. Thus, this ...
Read More
This book provides readers with the most up-to-date practical information on breast cancer screening. Since breast cancers are highly heterogeneous, time to clinical onset from the initial carcinogenesis differs diversely between cancers. Pathological germline variants and driver mutations cause a high lifetime risk of breast cancer. The lifetime risks are various according to what genes are pathologically dysfunctional. Integrated omics and imaging technologies have established varying tumour characteristics. Thus, this book suggests that a more individualised scheme is required to improve breast cancer screening. A key aim is to demonstrate how multiple diagnostic imaging modalities such as mammography, ultrasonography, MRI, PET and dbPET improve breast cancer screening accuracy. Mammography screening alone may have a limited impact on breast cancer risk prediction. These issues are crucial to discuss. Clinical experts recommend that new modalities be incorporated for women with dense breasts, like ultrasonography, dynamic mammography, MRI and maybe breast-dedicated PET. Topics on these modalities are going to be summarized in this book. An in-depth review of these modalities is summarised in this book. In addition, new diagnostic modalities, including risk assessment tools, multi-cancer early detection tests using liquid biopsy, the role of protein biomarkers in breast cancer risk screening, challenges, and hopes for future advances, are also covered in this book.
Read Less
Add this copy of Screening and Risk Reduction Strategies for Breast to cart. $112.31, like new condition, Sold by Open Books Ltd rated 5.0 out of 5 stars, ships from Chicago, IL, UNITED STATES, published 2023 by Springer.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Fine. Open Books is a nonprofit social venture that provides literacy experiences for thousands of readers each year through inspiring programs and creative capitalization of books.
Add this copy of Screening and Risk Reduction Strategies for Breast to cart. $159.69, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2023 by Springer.
Add this copy of Screening and Risk Reduction Strategies for Breast to cart. $173.63, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Santa Clarita, CA, UNITED STATES, published 2024 by Springer.
Add this copy of Screening and Risk Reduction Strategies for Breast to cart. $219.11, new condition, Sold by Just one more Chapter rated 4.0 out of 5 stars, ships from Miramar, FL, UNITED STATES, published 2024 by Springer.
Add this copy of Screening and Risk Reduction Strategies for Breast to cart. $220.68, new condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Santa Clarita, CA, UNITED STATES, published 2024 by Springer.
